World Health Organization. Cardiovascular diseases (CVDs) –Fact sheet, 2023.2.Neumann FJ, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019.3.Boden WE, et al. Optimal medical therapy with or without PCI. N Engl J Med. 2020.4.Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, 2021.5.Stone GW, et al. Outcomes after PCI: real-world data. JACC. 2021.6.Fox K, et al. Percutaneous coronary interventions in stableangina. BMJ. 2021.7.Patel MR, et al. ACC/AHA guidelines for stable ischemic heart disease. Circulation. 2021.8.Fihn SD, et al. Strategies for ischemic heart disease: invasive vs conservative. JAMA. 2019.9.Bhatt DL, et al. Invasive vs conservative therapy in stable ischemic heart disease. NEJM. 2022. Министерство здравоохранения Республики Узбекистан. Статистика по сердечно-сосудистым заболеваниям. 2023.11.Махмудов Ш.К. и др. Эпидемиология ИБС в Узбекистане. Узмеджурнал, 2022.12.Weintraub WS, et al. PCI and long-term survival. JACC. 2021.13.Hachamovitch R, et al. Revascularization vs medical therapy. JACC. 2019.14.Dagenais GR, et al. Long-term outcomes with medical therapy. Circulation. 2020.15.Yusuf S, et al. Modifiable risk factors in MI: INTERHEART study. Lancet. 2020.16.Windecker S, et al. Revascularization strategies. Eur Heart J. 2022.17.Бобоев Х.Б. и др. Сравнение лечения ИБС в Узбекистане. Журн. кардиологии, 2023.18.Nallamothu BK, et al. Risk-benefit in coronary interventions. Circulation. 2020.19.Goyal A, et al. Clinical outcomes in ischemic heart disease. JAMA Intern Med. 2023.20.Malkin CJ, et al. PCI in elderly patients. Heart. 2020.